Skip to main content
Log in

A dynamic model of price competition and promotion in prescription drug markets

  • Published:
Marketing Letters Aims and scope Submit manuscript

Abstract

In prescription drug markets, the effects of advertising on demand for the drug category and for specific brands have been studied, and the interaction between price and non-price promotions, acting on demand for the drug, is well established. More recently, supply-side decisions such as competitive pricing strategies between rival firms in the same therapeutic category, and the interaction between them and consumer advertising have been examined. The study extends the research on the relationship between competitive pricing strategies and direct-to-consumer advertising (DTCA) by developing and estimating a dynamic model in which sales is influenced by a combination of consumer advertising, detailing, and pricing. The model is estimated using US data from two medical therapeutic categories. One of these datasets has been used in estimation of a static model in a recently published study, and we compare the results of our dynamic model with the static model results. A dynamic model is appropriate for a market where there is a limited period and planning horizon for recovering the costs of drug development before a branded prescription drug loses its patent protection. The relationship between DTCA, detailing, and pricing under different competitive strategies is examined empirically. It is found that the dynamic model can contradict a basic conclusion of a static model, regarding mode of competitive pricing behavior. The relationship between amount and type of DTCA and competitive pricing strategy is as found in previous studies. There are implications for the marketing of pharmaceutical brands during their period of patent protection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Akaike, H. (1974). A new look at the statistical model identification. IEEE Transactions on Automatic Control, 19, 716–723.

    Article  Google Scholar 

  • Ailawadi, K., Kopalle, P., & Neslin, S. (2005). Predicting competitive response to a major policy change; Combining game-theoretic and empirical analysis. Marketing Science, 24, 12–24.

    Article  Google Scholar 

  • Amaldoss, W., & He, C. (2009). Direct-to-consumer advertising of prescription drugs: A strategic analysis. Marketing Science, 28, 472–487.

    Article  Google Scholar 

  • Bala, R. P., & Bhardwaj, P. (2010). Detailing vs. direct-to-consumer advertising in the prescription pharmaceutical industry. Management Science, 56, 148–160.

    Article  Google Scholar 

  • Chintagunta, P. K., & Desiraju, R. (2005). Strategic pricing and detailing behavior in international markets. Marketing Science, 24, 167–180.

    Article  Google Scholar 

  • Cyrenne, P. (1997). Price leadership and vertical relationships. Canadian Journal of Economics, 30, 235–245.

    Article  Google Scholar 

  • Deneckere, R., Kovenock, R. D., & Lee, R. (1992). A model of price leadership based on consumer loyalty. The Journal of Industrial Economics, 40, 147–154.

    Article  Google Scholar 

  • Dowrick, S. (1986). von Stackelberg and Cournot duopoly: Choosing roles. The RAND Journal of Economics, 17, 251–261.

    Article  Google Scholar 

  • Fischer, M., & Albers, S. (2010). Patient- or physician-oriented marketing: What drives primary demand for prescription drugs? Journal of Marketing Research, 47, 103–121.

    Article  Google Scholar 

  • Gal-Or, E. (1985). Information sharing in oligopoly. Econometrica, 53, 329–343.

    Article  Google Scholar 

  • Hausman, J. A. (1978). Specification tests in econometrics. Econometrica, 46, 1251–1271.

    Article  Google Scholar 

  • Mintzes, B., Barer, M. L., Kravitz, R. L., Bassett, B., Lexchin, J., Kazanjian, A., Evans, R. G., Pan, R., & Marion, S. A. (2003). How does direct-to-consumer Advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA. Canadian Medical Association Journal, 50, 1704–1715.

    Google Scholar 

  • Mukherji, P., Janakiraman, R., Dutta, S., & Rajiv, S. (2017). How direct-to-consumer advertising for prescription drugs affects consumers’ welfare: A natural experiment tests the impact of FDA legislation. Journal of Advertising Research, 57, 194–208.

    Article  Google Scholar 

  • Narayanan, S., Desiraju, R., & Chintagunta, P. K. (2004). Return on investment implications for pharmaceutical promotional expenditures: The role of marketing-mix interactions. Journal of Marketing, 68, 490–505.

    Article  Google Scholar 

  • Pazgal, A., Soberman, D., & D.A., & Thomadsen, R. (2016). Profit-increasing asymmetric entry. International Journal of Research in Marketing, 33, 107–122.

    Article  Google Scholar 

  • Pierce, D. A. (1977). Relationships and the lack thereof between economic time series. Journal of the American Statistical Association, 72, 11–26.

    Google Scholar 

  • Pinto, M. B. (2000). On the nature and properties of appeals used in direct-to-consumer advertising of prescription drugs. Psychological Reports, 86, 597–607.

    Article  Google Scholar 

  • Raju, J. S., & Roy, A. (2000). Market information and firm performance. Management Science, 46, 1075–1084.

    Article  Google Scholar 

  • Rizzo, J. A. (1999). Advertising and competition in the ethical pharmaceutical industry: The case of antihypertensive drugs. The Journal of Law and Economics, 42, 89–116.

    Article  Google Scholar 

  • Roth, M. S. (2003). Media and message effects on DTC prescription drug print advertising awareness. Journal of Advertising Research, 43, 180–193.

    Article  Google Scholar 

  • Roy, A., & Raju, J. S. (2011). The influence of demand factors on dynamic competitive pricing strategy: An empirical study. Marketing Letters, 22, 259–281.

    Article  Google Scholar 

  • Roy, A., Kim, N., & Raju, J. S. (2006). Assessing new empirical industrial organization (NEIO) methods: The cases of five industries. International Journal of Research in Marketing, 23, 369–383.

    Article  Google Scholar 

  • Roy, A., Hanssens, D. M., & Raju, J. S. (1994). Competitive pricing by a price leader. Management Science, 40, 809–823.

    Article  Google Scholar 

  • Roy, A., & Schramm, M. E. (2020). The relationship between competitive pricing and direct-to-consumer advertising: How to manage DTC advertising of Rx drugs in an integrated marketing mix strategy. Journal of Advertising Research, 60(3), 305–323.

    Article  Google Scholar 

  • Rust, R. T., & Schmittlein, D. C. (1985). A Bayesian cross-validated likelihood method for comparing alternative specifications of quantitative models. Marketing Science, 4, 375–393.

    Article  Google Scholar 

  • Schramm, M. E., Herbst, J. L., & Mattie, A. (2014). The false claims act: A review and policy recommendations. International Journal of Pharmaceutical and Healthcare Marketing, 8, 295–313.

    Article  Google Scholar 

  • Sridhar, S., Narayanan, S., & Srinivasan, R. (2014). Dynamic relationships among R&D, advertising, inventory and firm performance. Journal of the Academy of Marketing Science, 2, 277–290.

    Article  Google Scholar 

  • Tyagi, R. K. (1999). Pricing patterns as outcomes of product positions. The Journal of Business, 72, 135–157.

    Article  Google Scholar 

  • Villas-Boas, M., & Zhao, Y. (2005). Retailer, manufacturers, and individual consumers: Modeling the supply side in the ketchup marketplace. Journal of Marketing Research, 41, 83–95.

    Article  Google Scholar 

  • Vuong, Q. H. (1989). Likelihood ratio tests for model selection and non-nested hypotheses. Econometrica, 57, 307–333.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Abhik Roy.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 24 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Roy, A. A dynamic model of price competition and promotion in prescription drug markets. Mark Lett 33, 577–591 (2022). https://doi.org/10.1007/s11002-022-09632-9

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11002-022-09632-9

Keywords

Navigation